Skip to main
PSNL
PSNL logo

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 70%
Buy 10%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis Inc has demonstrated strong financial performance, with a 59% increase in biopharma testing and services revenue, reaching $51 million in 2024, up from $32 million in 2023. The company achieved a gross margin of 27.1% in the fourth quarter of 2024, surpassing consensus expectations and reflecting a favorable customer mix alongside increased biopharma volume. Furthermore, the continuous growth in NeXT Dx and NeXT Personal test volumes, with a notable 53% rise, underscores the increasing demand for Personalis's genomic sequencing solutions and their successful partnerships in the market.

Bears say

Personalis Inc.'s financial outlook appears negative due to a significant decline in operating revenue, with 4Q24 revenue reported at $16.8 million, a 15% decrease year-over-year, which fell short of market expectations. Additionally, the company's revenue from biopharma, particularly from the ImmunoID NeXT platform, is expected to weaken in 2025 following the completion of enrollment in a key clinical study, suggesting challenges ahead in revenue generation. The risks of slower customer adoption of new products, increased competition, and declining income from the VA MVP program further contribute to a cautious outlook for the firm's financial performance.

Personalis Inc (PSNL) has been analyzed by 10 analysts, with a consensus rating of Buy. 70% of analysts recommend a Strong Buy, 10% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 10 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.